Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryElite trio prompt Anthropic’s $1.5bn JV with Blackstone, Hellman and GoldmanLaw firmsTom Cox5 May 2026Freshfields and Slaughters advise as EQT tables improved bid for FTSE 100 IntertekLaw firmsWill Lewallen5 May 2026Trading Places: Paul Weiss and Kirkland grow in Houston, while Gibson Dunn hires Sullivan & Cromwell appellate co-headLaw firmsKate Peacock5 May 2026S&C and HSF Kramer lead as Lazard acquires Campbell Lutyens in latest secondaries tie-upLaw firmsWill Lewallen1 May 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025Former Freshfields senior partner among recipients in New Year Honours ListLaw firmsTom Cox2 Jan 2025Kramer Levin’s Paris office joins Morgan Lewis amid HSF merger dealLaw firmsTom Cox20 Dec 2024